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OUTCOMES OF INITIAL THERAPY
Current treatment guidelines, which advocate amphotericin B 
as induction therapy, are based on a large randomised
controlled trial (RCT) from the USA that compared initial
therapy with amphotericin B (0.7 mg/kg/d) plus or minus
flucytosine for 2 weeks, followed by 8 weeks of consolidation
treatment with either fluconazole (400 mg/d) or itraconazole
(400 mg/d).9 The overall mortality rate was 9.4% in the first 10
weeks, the lowest of any published trial, with flucytosine
associated with lower relapse rates and a trend toward a
higher proportion of negative cerebrospinal fluid (CSF)
cultures at 2 weeks. Fluconazole was superior to itraconazole
as consolidation therapy. However, the sickest patients, notably
those with a decreased level of consciousness, were excluded
from the study. A 10-week mortality rate of 26% has been
reported in a less selected US series of amphotericin B-treated
patients,10 and the rate was 33% in a Cape Town cohort of
patient receiving amphotericin B 1 mg/kg/d for a median of 7
days.11 Even compared with these unselected series, results
with fluconazole monotherapy (200 - 400 mg/d) as initial
therapy are disappointing. One small RCT found that
fluconazole 400 mg/d was inferior to amphotericin
B 0.7 mg/kg/d plus flucytosine,12 and although a larger RCT
comparing fluconazole 200 - 400 mg/d with amphotericin
B 0.4 - 0.5 mg/kg/d found no significant difference between
groups in overall mortality, there were trends in favour of
amphotericin B: the mortality in the first 2 weeks was higher
in the fluconazole treatment arm (15% v. 8%), and the median
time to culture-negative CSF was 64 days for fluconazole
versus 42 for amphotericin.13 Overall mortality in both
treatment groups of this study was high, and the dosage of
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Cryptococcal meningitis is a major cause of morbidity and mortality in African AIDS patients, accounting for between 13% and
17% of deaths in Ugandan HIV-infected individuals1,2 and 44% of deaths in a cohort of HIV-seropositive South African miners.3
This burden of disease is a result of high incidence, especially in southern and East Africa, and high acute mortality.4-6 In much
of Africa, fluconazole rather than amphotericin B was, and still is, widely used as initial therapy, for a variety of reasons. These
include the availability of fluconazole through free access programmes and in generic form, and the attractiveness of an easy
to use, safe oral regimen over a difficult to administer intravenous drug with significant side-effects, requiring inpatient
admission and close laboratory monitoring. In addition, in the absence of antiretroviral therapy, treatment of cryptococcal
meningitis has in the recent past been palliative rather than curative, reducing the rationale for more aggressive therapy, if this
is associated with increased side-effects. However, what data there are suggest that outcomes with fluconazole at
conventional dosage (up to 400 mg/d) as initial therapy are poor. In addition, the cost of amphotericin B, previously
considerable in South Africa, has been reduced.7 More importantly, increasing access to antiretroviral therapy (ART) now means
that the long-term prognosis of patients with cryptococcal meningitis is good, provided they survive the acute infection.8 We
summarise the evidence that a factor contributing to high acute mortality in cryptococcal meningitis is the inadequacy of
fluconazole at up to 400 mg/d as an induction regimen, and present the case for initial treatment with amphotericin B in South
Africa, where feasible.
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amphotericin B, which has concentration-dependent activity,
was less than currently recommended, making interpretation
difficult.
African studies also show unfavourable outcomes with initial
fluconazole treatment at 200 - 400 mg/d. In a series from
Zambia the median survival with fluconazole 200 mg/d
monotherapy was 19 days compared with10 days in untreated
patients.5 Mortality with fluconazole 200 mg/d in a Ugandan
trial was 40% in the first 2 weeks and 64% at 2 months.14
Schaars et al. demonstrated a 10-week mortality of
approximately 50% with either 200 or 400 mg/d in a study in
Cape Town.6 This is almost certainly an underestimate given
the retrospective nature of the study. Of note, although many
of these studies were carried out prior to availability of ART,
two studies suggest that access to ART does not affect the
acute, 10-week mortality from cryptococcal meningitis.11,15 The
evidence therefore suggests that the 10-week mortality in
unselected patients treated with fluconazole at up to
400 mg/d is significantly more than 50% in most African
settings.
FUNGISTATIC VERSUS FUNGICIDAL TREATMENT
In contrast to amphotericin B, which is fungicidal, standard
dose fluconazole is effectively fungistatic. Time to culture
negativity has consistently been shown to be longer with
fluconazole than with amphotericin-based regimens.11,12 In the
RCT of fluconazole 400 mg versus amphotericin 0.7 mg/kg
plus flucytosine the mean time to CSF sterilisation was 41 days
with fluconazole and 16 days with amphotericin B.12 Recent
work in Cape Town, using serial quantitative cultures to
measure the rate of clearance of cryptococcal colony-forming
units from the CSF (also called early fungicidal activity or EFA),
has further demonstrated that the clearance of cryptococci
from the CSF over the first 2 weeks is significantly faster with
amphotericin (given for 1 week at a dosage of 1 mg/kg/d) than
fluconazole (400 mg/d), fluconazole being almost fungistatic
over this time period (Fig. 1).11
There is evidence that the rapidity of CSF sterilisation is related
to clinical outcome. Two-week CSF culture status has been
shown to be associated with outcome at 10 weeks by
multivariate analysis.10 In addition, by pooling data from
patients studied with serial quantitative CSF cultures in
Thailand, Cape Town and Uganda, we have increasing evidence
that rate of clearance of infection is associated with mortality,
independent of altered mental status at presentation and
baseline organism load, the other two major prognostic factors
(author's unpublished data). 
DRUG RESISTANCE
The fungistatic nature of fluconazole as initial therapy may 
promote the development of drug resistance because of
ongoing high fungal burdens and drug exposure over
prolonged periods. Surveillance data from South Africa have
shown an increase in the percentage of Cryptococcus
neoformans isolates with fluconazole resistance.16,17 In a
prospective study in Cape Town looking at symptomatic
relapse of cryptococcal meningitis in patients who had
received initial fluconazole therapy (400 mg/d), two-thirds of
relapses were culture positive. Over half of these were
associated with C. neoformans isolates with high-level
resistance to fluconazole (Fig. 2). Outcomes in these patients
were poor, with prolonged hospital admissions and
considerable mortality despite prolonged treatment with
amphotericin B.16
CRYPTOCOCCAL MENINGITIS IMMUNE
RECONSTITUTION SYNDROME
A further concern resulting from the prolonged high fungal
burden associated with fluconazole therapy is the possibility of
predisposition to immune reconstitution syndromes (IRIS)
following initiation of ART. Cryptococcal IRIS has been
reported in up to 30% of patients with cryptococcal meningitis
following ART,18,19 and high rates, with associated mortality,
have been reported in South African cohorts treated with
initial fluconazole therapy.20 An association between high rates
EFA= –0.48 ± 0.28 log CFU/d
(N=49)
EFA= –0.02 ± 0.05 log CFU/d
(N=5)
Fig. 1. Decrease in CSF Cryptococcus neoformans colony-
forming units (CFU) over time, by treatment group. The
decrease in log CFU per ml of CSF per day was calculated for
each patient using the slope of the linear regression of log
CFU against time. For each treatment group, early fungicidal
activity (EFA) is shown as the mean±SD rate of decrease in log
CFU counts. EFA was significantly greater for amphotericin B,
compared with fluconazole (p=0.001 (from Bicanic et al.,11
with permission).
AmB 1 mg/kg
Flu 400 mg/d
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of cryptococcal IRIS and fluconazole as initial treatment as
opposed to amphotericin B has not been demonstrated, but
would be consistent with the existing data on risk factors for
the development of IRIS. Cryptococcal IRIS is associated with
a high fungal burden at baseline (high antigen titres and
disseminated disease), early introduction of ART (within 1 - 2
months of diagnosis of cryptococcal disease, when fungal
burdens are likely to be higher), and persistently positive CSF
cultures after 2 weeks.18,19 Experience from Cape Town
suggests that the rates of cryptococcal IRIS may have declined
since the introduction of amphotericin B as initial therapy.20,21
CONCLUSIONS
The balance of evidence suggests that amphotericin B (0.7 - 1
mg/kg/d)-based regimens are superior to fluconazole 400
mg/d as induction therapy for HIV-associated cryptococcal
meningitis. Amphotericin B induction therapy should be used
where possible, with sodium and fluid loading, equivalent to
1 litre normal saline per day, if there are no contraindications,
and the patient is carefully monitored for anaemia, renal
impairment and electrolytes, and receives potassium
replacement therapy as required. In the absence of flucytosine,
a dosage of 1 mg/kg/d for up to 2 weeks is usually tolerated.
Significant side-effects, if they occur, usually do so in the
second week, by which time the organism load will have been
significantly reduced and patients can be switched early to
fluconazole if necessary.8,11,22 In the many settings (especially
common in the rest of Africa) where amphotericin B therapy
is still not feasible, fluconazole should be used at a dosage of
at least 800 mg/d, pending the results of studies, currently
under way, to optimise oral treatment regimes in such
settings. There is a linear plasma level-dose relationship with
fluconazole doses up to 2 g/d,23 and some evidence for a dose-
response effect with higher fluconazole doses, in terms of
time to sterilisation of CSF.12,13,24,25 Dosages up to 1 600 mg/d
have been used in limited numbers of patients without serious
side-effects.23,26
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Fig. 2. Minimum inhibitory concentrations (MICs) of
fluconazole for 20 Cryptococcus neoformans isolates
recovered from patients with culture-positive relapse of
cryptococcal meningitis. For 1 isolate from a patient with
culture-positive relapse, sensitivity data were not available
(from Bicanic et al.,16 with permission).
MIC, µg/ml
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